Loading...
Market
Will the new oral immunotherapy for babies with peanut allergy in Australia have a success rate above 75% by the end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official reports from Australian health authorities or published studies
Story
Australia Introduces World-First Oral Immunotherapy for Babies with Peanut Allergy
Jul 31, 2024, 02:04 AM
Australia has initiated a groundbreaking peanut allergy treatment for babies, marking the first time oral immunotherapy will be offered as part of a new standardised model of care in hospitals across the country. This world-first initiative aims to address the growing prevalence of peanut allergies among infants by providing a structured and controlled treatment protocol. The new approach is expected to significantly improve the quality of life for affected families and reduce the risk of severe allergic reactions. This landmark health initiative sets a new precedent in allergy treatment.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Abbott found liable • 25%
Abbott not found liable • 25%
Mistrial declared • 25%
Case dismissed • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Mostly positive • 25%
Mixed • 25%
Mostly negative • 25%
Unchanged • 25%
Yes • 50%
No • 50%
